Table II.
Indication for treatment of patients undergoing urgent/emergent patients in March-April 2020 and 2019
| Variable | 2020: 116 patients | 2019: 34 patients | P |
|---|---|---|---|
| Acute limb ischemia | 31 (26.7%) | 6 (17.6%) | 0.28 |
| Native arterial tree thrombosis | 28 (90.3%) | 5 (83.3%) | |
| Previous femoropopliteal graft thrombosis | 3 (9.7%) | 1 (16.7%) | |
| Chronic limb-threatening limb ischemia | 24 (20.7%) | 1 (2.9%) | 0.015 |
| Irreversible lower limb ischemia, gangrene | 6 (5.2%) | 0 (0%) | 0.176 |
| Aortic pathology | 21 (18.1%) | 6 (17.6%) | 0.951 |
| Stanford B acute AD | 2 (9.5%) | 2 (33.3%) | |
| TAAA | 4 (19.0%) | 2 (33.3%) | |
| TAA | 2 (9.5%) | 0 (0%) | |
| AAA | 13 (61.9%) | 2 (33.3%) | |
| Symptomatic carotid stenosis | 17 (14.7%) | 5 (14.7%) | 0.994 |
| Other | 17 (14.7%) | 16 (47.1%) | <0.001 |
| Cardiogenic shock necessitating ventricular assist devices | 2 (1.7%) | 5 (14.7%) | 0.002 |
AD, aortic dissection; TAAA, thoracoabdominal aortic aneurism; TAA, thoracic aortic aneurysm; AAA, abdominal aortic aneurysm. Bold indicates the results reaching statistical significance (P < .05).